The role of small molecule NMR in medicinal chemistry
ABOUT THIS WEBINAR
Since its early days, nuclear magnetic resonance (NMR) has played an important role in the pharmaceutical industry. NMR is traditionally used by medicinal chemists for structure elucidation of both synthesised molecules and active compounds isolated from natural sources. However, it can also be a valuable tool for reaction monitoring, the characterisation of solution conformations, the investigation of metabolites, hit-to-lead optimisation and quantitation.
In this webinar, Kathleen Farley (Senior Principal Scientist, R&D, Pfizer Inc) will describe how NMR spectroscopy is integrated into the Pfizer drug discovery pipeline and how the technique is used in a walk-up environment by medicinal chemists and NMR scientists to solve challenging drug discovery problems.
Additionally, Anna Codina (Director Pharmaceutical Business Unit, Bruker BioSpin) will finish the webinar by presenting new additions to the NMR instrumentation family that make the technique available to a wider audience, overcoming some of the current cost concerns. This expansion includes both affordable high-resolution and benchtop instrumentation.
- The role of NMR as a key technique to support medicinal chemistry
- How scientists at Pfizer use NMR to accelerate drug discovery
- Examples of NMR instrumentation in walk-up labs
- The benefits of investing in NMR
- How NMR has become widely available with affordable high-resolution and benchtop instrumentation
Kathleen Farley, Senior Principal Scientist, R&D, Pfizer Inc
Kathleen Farley is a Senior Principal Scientist in the R&D division at Pfizer Inc with over 30 years of experience in the pharmaceutical industry providing NMR support for Medicinal Chemistry research. She has taught the American Chemical Society (ACS) NMR course, “1D and 2D NMR Spectroscopy: Structure Determination of Small Molecule Organic Compounds” with Greg Walker for the last 10 years. Kathleen also has over 40 publications including a book chapter and two patents. Her current research includes the structural characterisation of small molecules and peptides using residual dipolar couplings.
Anna Codina, Director Pharmaceutical Business Unit, Bruker BioSpin
Anna has a degree in Chemistry and a PhD in Protein NMR from the University of Barcelona, Spain. She undertook her post-doc in protein NMR at the MRC Laboratory of Molecular Biology in Cambridge, UK, and following that worked in the Analytical R&D department of Pfizer for eight years, becoming proficient in low level impurity structure elucidation, reaction monitoring, qNMR and the preparation of regulatory documentation.
She joined Bruker in 2011 as Material Characterisation Laboratory Manager and has since moved up to being the Director of the Pharmaceutical Business Unit at Bruker BioSpin.